RecruitingNCT07611838

Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction

Multi-Omics Data-Derived Inflammatory Phenotype for ABPA Recurrence Risk Prediction: A Multicenter Study

Sponsor

Qianfoshan Hospital

Enrollment

300 participants

Start Date

Jan 1, 2021

Study Type

OBSERVATIONAL

Conditions

Relapse Multicenter Study Multi-omics Machine Learning Allergic Bronchopulmonary Aspergillosis (ABPA)

Summary

To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria2

Female and Male patients aged 18-80 years
diagnosis of Allergic Bronchopulmonary Aspergillosis ABPA accroding to the 2024 ISHAM Working Group Diagnostic Criteria

Exclusion Criteria5

Patients with malignant tumors or severe organ dysfunction (e.g., cardiac, cerebral, renal, etc.)
Patients with severe comorbidities, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease (CKD stage 5), decompensated cirrhosis, etc.
Patients with immunosuppressive status, such as HIV infection, long-term use of oral corticosteroids or immunosuppressive agents.
Pregnant or lactating women.
Patients with missing key data or incomplete medical records.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China, Jinan, Shandong 250014

Jinan, Shandong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07611838